Company: SISI
Filing Date: 2025-02-14
Form Type: 10-Q
Source: 0001493152-25-006895
Chunk: 194

Company: SHINECO, INC.
Filing Date: 2025-02-14
Form: 10-Q
Item: Part I, Item 2
Chunk 194
---
-  
     114,945  
     100.00%
  
    Investment income from derivative financial assets 
     1,962  
     766  
     1,196  
     156.14%
  
    Other income, net 
     322,030  
     274,065  
     47,965  
     17.50%
  
    Amortization of debt issuance and other costs 
     (146,976) 
     (199,234) 
     52,258  
     (26.23)%
  
    Interest expenses, net 
     (185,524) 
     (452,090) 
     266,566  
     (58.96)%
  
    Loss before income tax benefit from continuing operations 
     (2,532,158) 
     (5,762,665) 
     3,230,507  
     (56.06)%
  
    Benefit for income taxes 
     (242,475) 
     (706,562) 
     464,087  
     (65.68)%
  
    Net loss from continuing operations 
     (2,289,683) 
     (5,056,103) 
     2,766,420  
     (54.71)%
  
    Net income from discontinued operations 
     -  
     -  
     -  
     - 
  
    Net loss 
    $(2,289,683) 
    $(5,056,103) 
    $2,766,420  
     (54.71)%
  
    Comprehensive loss attributable to Shineco Inc. 
    $(1,817,740) 
    $(4,312,924) 
    $2,495,184  
     (57.85)%

Revenue

Currently,
we, through our PRC subsidiaries, have three major business segments from continuing operations. First, developing, producing and distributing
innovative rapid diagnostic and other products and related medical devices for the most common diseases; this segment is conducted through
Biowin. Second, producing, processing and distributing silk products, and providing fruit trading business; this segment is conducted
through Wintus. Third, developing and selling healthy meals for people with slow metabolic health and those in recovery from metabolic